Abstract
Herpes-Simplex Virus type 2 (HSV-2) is a lifelong infection, which has infected over 400 million individuals aged 15-49 years, worldwide. While the disease can be treated with episodic and suppressive antiviral drugs to reduce the rate of recurrence (i.e., symptomatic disease) and viral shedding, none of the currently available therapies can clear the virus from the body of an infected person. A number of therapeutic vaccine platforms are currently in development in order to achieve similar effects to treatment. Due to the inadequate data from clinical trials of therapeutic vaccines, modeling efforts to quantify the impact of vaccination have been limited. In this study, we propose a compartmental deterministic model for the dynamics of HSV-2 to evaluate the effect of a potential vaccine candidate with the inclusion of a booster dose. Despite its simplicity that may not address the complexity of HSV-2 disease, the model shows that targeting symptomatic infection for vaccination is the most effective strategy in the long-term. This conclusion is based on the assumption of an optimal vaccine efficacy, conferring immunity levels that prevent viral shedding and recurrence transiently. Our model provides a framework for developing a...Continue Reading
References
Jun 1, 1988·Vaccine·L KutinováE Domorázková
Mar 13, 1986·The New England Journal of Medicine·L Corey, P G Spear
Jun 1, 1983·Annals of Internal Medicine·L CoreyK K Holmes
Sep 1, 1983·The Journal of Antimicrobial Chemotherapy·L CoreyJ Dragavon
Jun 11, 1994·Lancet·S E StrausS F Adair
Dec 1, 1994·Annals of Internal Medicine·J BenedettiR Ashley
Feb 7, 2001·Sexually Transmitted Infections·R PatelD M Grant
Aug 19, 2000·Sexually Transmitted Diseases·E A Newton, J M Kuder
Sep 28, 2002·The Journal of Infectious Diseases·Jennifer S Smith, N Jamie Robinson
Jan 2, 2004·The New England Journal of Medicine·Lawrence CoreyUNKNOWN Valacyclovir HSV Transmission Study Group
Feb 3, 2004·Sexually Transmitted Infections·G P GarnettT Darcis
May 7, 2004·The New England Journal of Medicine·David W Kimberlin, Dwight J Rouse
Apr 20, 2005·The Journal of Infectious Diseases·Elissa J Schwartz, Sally Blower
Oct 11, 2005·Vaccine·Guy de BruynLawrence Corey
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Rachna Gupta, Anna Wald
Sep 21, 2007·Human Vaccines·Elissa J SchwartzSally Blower
Mar 31, 2010·Sexually Transmitted Diseases·Ramzi A AlsallaqLaith J Abu-Raddad
Apr 14, 2011·JAMA : the Journal of the American Medical Association·Elizabeth TronsteinAnna Wald
Sep 29, 2011·Vaccine·Anna WaldPramod K Srivastava
Jan 22, 2015·PloS One·Katharine J LookerLori M Newman
Mar 23, 2017·The Journal of Infectious Diseases·David I BernsteinSeth Hetherington
May 20, 2019·Vaccine·David I BernsteinUNKNOWN Genocea study group